Imfinzi approved in the US for endometrial cancer
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Nadda expressed his concern about growing incidence of Non-Communicable Diseases and the importance of awareness regarding healthy diet and lifestyle
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Accelerating sustainability in Indian pharma industry
Subscribe To Our Newsletter & Stay Updated